Gas6 and Soluble MerTK in Periodontal Diseases
ConditionPeriodontitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAbant Izzet Baysal University
About this trial
This study aimed to investigate gingival crevicular fluid (GCF) and serum soluble MerTK (sMerTK) and Gas6 levels in periodontal health and disease. A total of 90 individuals, 30 patients with stage III grade B periodontitis, 30 with gingivitis and 30 periodontally healthy individuals were included. Whole-mouth and site-specific clinical periodontal parameters including probing depth, clinical attachment level, bleeding on probing, gingival index, plaque index were recorded. GCF and serum sMerTK and Gas6 levels were measured by enzyme-linked immunosorbent assay. Statistical analysis was performed by using non-parametric tests.
Eligibility criteria
Qualifiers
Individuals without systemic diseases that may affect periodontal tissues (such as cardiovascular diseases, atherosclerosis, immune system disorders, rheumatoid arthritis, obesity, cancer, and diabetes)
Individuals who have not used antibiotics within the last 3 months
Individuals not taking any medications known to affect periodontal tissues
Individuals without infectious diseases such as HIV, hepatitis B virus (HBV), or tuberculosis
Disqualifiers
Pregnant or lactating individuals
Individuals who have received periodontal treatment within the last 6 months
Current smokers
Trial design
Treatments tested in this trial
- gingival crevicular fluid collection
Treatment groups
90 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov